阿尔茨海默病连续体中的目标身体功能:与ALBION研究中的脑脊液生物标志物的关联
Stefanos N Sampatakakis1, Eirini Mamalaki1, Eva Ntanasi1
11st Department of Neurology, Aiginition Hospital, National and Kapodistrian University of Athens Medical School, 11528 Athens, Greece.
International journal of molecular sciences
|September 28, 2023
概括
轻度认知障碍 (MCI) 患者的步行速度较慢与大脑粉样β (Aβ42) 沉积水平较高有关,这是阿尔茨海默病 (AD) 的关键生物标志物. 这种关联强调了移动性和AD进展之间的联系.
科学领域:
- 神经科学是一个神经科学.
- 老年学是一门学科.
- 生物标志物研究 生物标志物研究
背景情况:
- 认知和身体衰退是衰老的标志.
- 身体功能与阿尔茨海默病 (AD) 生物标志物之间的关系需要进一步研究.
研究的目的:
- 检查AD连续体中物理功能参数 (步行时间,手握强度) 和脑脊液 (CSF) 生物标志物 (Aβ42,Tau,PhTau) 之间的关系.
- 在认知正常 (CN) 和轻度认知障碍 (MCI) 个体中探索这些关系.
主要方法:
- 分析了来自40至75岁的163名参与者 (112名CN,51名MCI) 的数据,这些参与者来自Aiginition Longitudinal Biomarker Investigation of Neurodegeneration研究.
- 在基线测量行走时间和手握强度,然后进行脊椎穿刺以采集CSF.
- 通过使用自动化方法和统计分析,包括线性相关性和多变量回归,评估CSF Aβ42,Tau和PhTau水平.
主要成果:
- 步行时间与所有参与者的CSFAβ42水平呈反向关系 (p <0.05),表明慢步行与大脑粉样蛋白沉积的增加有关.
- 这种关联在患有MCI和60岁以上的人群中更为明显.
- 在调整年龄,性别,教育程度和APOEe4基因型后,这些发现仍然具有统计学意义.
结论:
- 身体移动性,特别是步行时间,与老龄化谱中个体的核心阿尔茨海默病神经病理学 (粉样β沉积) 有关.
- 移动性可能是阿尔茨海默氏症早期疾病的潜在指标或促成因素.
- 这些结果表明了关于运动功能在AD连续性中的作用的新视角.
更多相关视频
相关概念视频
Alzheimer's Disease: Overview
513
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
513
Alzheimer's Disease: Treatment
212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212


